| Budget Amount *help |
¥193,570,000 (Direct Cost: ¥148,900,000、Indirect Cost: ¥44,670,000)
Fiscal Year 2022: ¥33,280,000 (Direct Cost: ¥25,600,000、Indirect Cost: ¥7,680,000)
Fiscal Year 2021: ¥37,960,000 (Direct Cost: ¥29,200,000、Indirect Cost: ¥8,760,000)
Fiscal Year 2020: ¥37,960,000 (Direct Cost: ¥29,200,000、Indirect Cost: ¥8,760,000)
Fiscal Year 2019: ¥42,770,000 (Direct Cost: ¥32,900,000、Indirect Cost: ¥9,870,000)
Fiscal Year 2018: ¥41,600,000 (Direct Cost: ¥32,000,000、Indirect Cost: ¥9,600,000)
|
|---|
| Outline of Final Research Achievements |
We showed that the expression of Regnase-1, a protein involved in the degradation of mRNA such as cytokines, in immune cells is associated with human pulmonary hypertension. We also discovered that mice lacking Regnase-1 in myeloid cell lineage cells naturally developed pulmonary hypertension. Furthermore, we succeeded in the development of nucleic acid therapeutics that enhance Regnase-1 expression and suppress inflammation was achieved by targeting the self-regulatory mechanism of Regnase-1. In addition, through analysis of the relationship between mRNA modification and blood cell differentiation, we found that mice lacking the RNA m6A methylation enzyme METTL16 exhibit severe anemia through DNA repair impairment. This finding demonstrates the important role of m6A modification mediated by METTL16 in hematopoietic cell differentiation.
|
| Assessment Rating |
Ex-post Assessment Comments (Rating)
A: In light of the aim of introducing the research area into the research categories, expected outcomes of research have been produced.
|
Assessment Rating |
Interim Assessment Comments (Rating)
A: In light of the aim of introducing the research area into the research categories, the expected progress has been made in research.
|
